Opioids often prescribed in low-income areas

Article Type
Changed
Thu, 02/14/2019 - 10:02

A new study published in JAMA Internal Medicine offers yet more evidence that the opioid epidemic affects a large proportion of low-income majority-white communities. Also today, undervaccination poses a particular danger to patients with HIV, patients with inflammatory bowl disease aren’t getting appropriate reproductive counseling, and the type of exercise does matter when it comes to preventing falls among elderly patients.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Publications
Topics
Sections

A new study published in JAMA Internal Medicine offers yet more evidence that the opioid epidemic affects a large proportion of low-income majority-white communities. Also today, undervaccination poses a particular danger to patients with HIV, patients with inflammatory bowl disease aren’t getting appropriate reproductive counseling, and the type of exercise does matter when it comes to preventing falls among elderly patients.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

A new study published in JAMA Internal Medicine offers yet more evidence that the opioid epidemic affects a large proportion of low-income majority-white communities. Also today, undervaccination poses a particular danger to patients with HIV, patients with inflammatory bowl disease aren’t getting appropriate reproductive counseling, and the type of exercise does matter when it comes to preventing falls among elderly patients.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica

Suicide: Igor Galynker

Article Type
Changed
Thu, 02/14/2019 - 09:40

In this episode, Igor Galynker, MD, stops by to talk about suicide with Lorenzo Norris, MD. One major topic of conversation centers around suicide-specific diagnosis. And later, Renee Kohanski, MD, talks about the importance of communication. You can listen to Dr. Galynker’s first appearance on the Psychcast here.

Amazon
Apple Podcasts
Google Podcasts
Spotify



 

Publications
Topics
Sections

In this episode, Igor Galynker, MD, stops by to talk about suicide with Lorenzo Norris, MD. One major topic of conversation centers around suicide-specific diagnosis. And later, Renee Kohanski, MD, talks about the importance of communication. You can listen to Dr. Galynker’s first appearance on the Psychcast here.

Amazon
Apple Podcasts
Google Podcasts
Spotify



 

In this episode, Igor Galynker, MD, stops by to talk about suicide with Lorenzo Norris, MD. One major topic of conversation centers around suicide-specific diagnosis. And later, Renee Kohanski, MD, talks about the importance of communication. You can listen to Dr. Galynker’s first appearance on the Psychcast here.

Amazon
Apple Podcasts
Google Podcasts
Spotify



 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica

Conservatism spreads in prostate cancer

Article Type
Changed
Tue, 02/14/2023 - 13:05

 

Watchful waiting is on the rise for low-risk prostate cancer, the United States now has more than 100 measles cases for the year, e-cigarette use reverses progress in reducing teens’ tobacco use, and consider adopting the MESA 10-year coronary heart disease risk calculator.

Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Publications
Topics
Sections

 

Watchful waiting is on the rise for low-risk prostate cancer, the United States now has more than 100 measles cases for the year, e-cigarette use reverses progress in reducing teens’ tobacco use, and consider adopting the MESA 10-year coronary heart disease risk calculator.

Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

 

Watchful waiting is on the rise for low-risk prostate cancer, the United States now has more than 100 measles cases for the year, e-cigarette use reverses progress in reducing teens’ tobacco use, and consider adopting the MESA 10-year coronary heart disease risk calculator.

Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica

Pregnant women want genome guidance

Article Type
Changed
Tue, 02/12/2019 - 16:57

 

Almost all pregnant women would want information about serious treatable childhood-onset conditions from non-invasive prenatal whole-genome sequencing. Also today, a look at asthma, obesity, and the risk for severe sleep apnea in children, new questions about the role that antinuclear antibodies are playing in systemic lupus erythematosus, and the lifetime cost of tobacco is nearly $2 million per smoker.

Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

 

Publications
Topics
Sections

 

Almost all pregnant women would want information about serious treatable childhood-onset conditions from non-invasive prenatal whole-genome sequencing. Also today, a look at asthma, obesity, and the risk for severe sleep apnea in children, new questions about the role that antinuclear antibodies are playing in systemic lupus erythematosus, and the lifetime cost of tobacco is nearly $2 million per smoker.

Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

 

 

Almost all pregnant women would want information about serious treatable childhood-onset conditions from non-invasive prenatal whole-genome sequencing. Also today, a look at asthma, obesity, and the risk for severe sleep apnea in children, new questions about the role that antinuclear antibodies are playing in systemic lupus erythematosus, and the lifetime cost of tobacco is nearly $2 million per smoker.

Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica

SGLT2s for heart failure first, diabetes second

Article Type
Changed
Mon, 02/11/2019 - 04:00

 

For patients with systemic heart failure but without diabetes, oral SGLT2s are the focus of multiple ongoing phase 3 clinical trials. Also today, influenza activity hits a seasonal high, the U.S. Supreme Court halts a Louisiana abortion law from taking effect, and cilostazol plus aspirin or clopidogrel reduces the risk of recurrent stroke.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

 

Publications
Sections

 

For patients with systemic heart failure but without diabetes, oral SGLT2s are the focus of multiple ongoing phase 3 clinical trials. Also today, influenza activity hits a seasonal high, the U.S. Supreme Court halts a Louisiana abortion law from taking effect, and cilostazol plus aspirin or clopidogrel reduces the risk of recurrent stroke.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

 

 

For patients with systemic heart failure but without diabetes, oral SGLT2s are the focus of multiple ongoing phase 3 clinical trials. Also today, influenza activity hits a seasonal high, the U.S. Supreme Court halts a Louisiana abortion law from taking effect, and cilostazol plus aspirin or clopidogrel reduces the risk of recurrent stroke.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

 

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica

500 Women in Medicine: Part I

Article Type
Changed
Tue, 03/12/2019 - 17:21

Kate Gerull and Maren Loe founded the non-profit 500 Women in Medicine.* Ms. Gerull and Ms. Loe are third-year medical students at Washington University School of Medicine in St. Louis.

Their aim is to create a network of support and advancement for women in medicine. 500 Women in Medicine is a pod of the organization 500 Women Scientists.

In this episode, Nick Andrews speaks with the two innovators about their motivation to found this organization.

Correction, 3/12/19: An earlier version of this article misstated Kate Gerull's name.

Apple Podcasts
Google Podcasts
Spotify

Publications
Topics
Sections

Kate Gerull and Maren Loe founded the non-profit 500 Women in Medicine.* Ms. Gerull and Ms. Loe are third-year medical students at Washington University School of Medicine in St. Louis.

Their aim is to create a network of support and advancement for women in medicine. 500 Women in Medicine is a pod of the organization 500 Women Scientists.

In this episode, Nick Andrews speaks with the two innovators about their motivation to found this organization.

Correction, 3/12/19: An earlier version of this article misstated Kate Gerull's name.

Apple Podcasts
Google Podcasts
Spotify

Kate Gerull and Maren Loe founded the non-profit 500 Women in Medicine.* Ms. Gerull and Ms. Loe are third-year medical students at Washington University School of Medicine in St. Louis.

Their aim is to create a network of support and advancement for women in medicine. 500 Women in Medicine is a pod of the organization 500 Women Scientists.

In this episode, Nick Andrews speaks with the two innovators about their motivation to found this organization.

Correction, 3/12/19: An earlier version of this article misstated Kate Gerull's name.

Apple Podcasts
Google Podcasts
Spotify

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.

Novel plasma biomarkers for Alzheimer’s

Article Type
Changed
Fri, 02/08/2019 - 04:00

 

A plasma proteomic study has identified new biomarkers for Alzheimer’s disease pathology in cognitively unimpaired individuals. Also today, biomarkers predict VTE risk with menopausal oral hormone therapy, there is a cloud of inconsistency hanging over cannabis data, and compounded pain creams are no better than placebo for chronic localized pain.

Amazon Alexa

Apple Podcasts

Google Podcasts

Spotify

 

Publications
Sections

 

A plasma proteomic study has identified new biomarkers for Alzheimer’s disease pathology in cognitively unimpaired individuals. Also today, biomarkers predict VTE risk with menopausal oral hormone therapy, there is a cloud of inconsistency hanging over cannabis data, and compounded pain creams are no better than placebo for chronic localized pain.

Amazon Alexa

Apple Podcasts

Google Podcasts

Spotify

 

 

A plasma proteomic study has identified new biomarkers for Alzheimer’s disease pathology in cognitively unimpaired individuals. Also today, biomarkers predict VTE risk with menopausal oral hormone therapy, there is a cloud of inconsistency hanging over cannabis data, and compounded pain creams are no better than placebo for chronic localized pain.

Amazon Alexa

Apple Podcasts

Google Podcasts

Spotify

 

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica

‘Simple’ way to cut PAD risk, misguided ED visits for atrial fib, and more

Article Type
Changed
Thu, 02/14/2019 - 09:41

 

This week in MDedge Cardiocast: Elevated CAC in highly active men doesn’t raise risk of death, Life’s Simple 7 scores can be used to modify PAD risk, medical guidance often leads atrial fibrillation patients to needlessly seek emergency department care, and thinking of pregnancy as a stress test can help predict women’s future cardiovascular risk.

Amazon AlexaApple Podcasts

Google Podcasts

TuneIn

Publications
Topics
Sections

 

This week in MDedge Cardiocast: Elevated CAC in highly active men doesn’t raise risk of death, Life’s Simple 7 scores can be used to modify PAD risk, medical guidance often leads atrial fibrillation patients to needlessly seek emergency department care, and thinking of pregnancy as a stress test can help predict women’s future cardiovascular risk.

Amazon AlexaApple Podcasts

Google Podcasts

TuneIn

 

This week in MDedge Cardiocast: Elevated CAC in highly active men doesn’t raise risk of death, Life’s Simple 7 scores can be used to modify PAD risk, medical guidance often leads atrial fibrillation patients to needlessly seek emergency department care, and thinking of pregnancy as a stress test can help predict women’s future cardiovascular risk.

Amazon AlexaApple Podcasts

Google Podcasts

TuneIn

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica

Biosimilars: Gary H. Lyman

Article Type
Changed
Wed, 02/27/2019 - 12:37

In this episode, Gary H. Lyman, MD (https://bitly.is/2UJzUly) joins David Henry, MD, (http://bit.ly/2MFDfzm) to talk about biosimilars. 

Dr. Lyman talks about the definition of biosimilars, how they are made, which are approved, and which ones are on the market. 

He also talks about extrapolation and interchangeability as well as where some biosimilars stand in both ASCO and NCCN guidelines for patients who are going into supportive care. 

And Ilana Yurkiewicz, MD (https://stanford.io/2RXPixR), talks about what the word "cure" means to you compared to what it means to patients in a world with OS, PFS, DFS, CR, etc. (26:35). 

Subscribe here:

Apple Podcasts
Google Podcasts

Show Notes

By Hitomi Hosoya, MD, PhD

- Biosimilars are biologic products that are highly similar to the reference products with no clinically meaningful difference in terms of safety, efficacy, purity, and potency.

- Unlike “generic” products, biosimilars are produced in living systems, therefore they cannot be replicated identically. 

- The Food and Drug Administration encourages companies to produce biosimilars as a patent expires on the original product.

- For approval, the FDA requires largely preclinical data; amino acid sequence and molecular structures, pharmacodynamics and pharmacokinetic data in animal models and humans. Also, no greater immunogenicity should be demonstrated.

- Large randomized trials are not usually required for approval of biosimilars as there is already data on the original product. Post-marketing surveillance is important.

- 14 biosimilars have already been approved by the FDA.

- Interchangeable designation of biosimilars is yet to come.

- At this early stage of biosimilar marketing, we see a 10%-11% cost reduction. This is expected to increase as the market expands.

References:

 JAMA Oncol.2018 Feb 1;4(2):241-247

 JCSO 2018;16(6):e283-e289.

Contact us: [email protected]

MDedge Hematology/Oncology Twitter: @MDedgeHemOnc

Ilana Yurkiewicz Twitter: @ilanayurkiewicz

 

Publications
Sections

In this episode, Gary H. Lyman, MD (https://bitly.is/2UJzUly) joins David Henry, MD, (http://bit.ly/2MFDfzm) to talk about biosimilars. 

Dr. Lyman talks about the definition of biosimilars, how they are made, which are approved, and which ones are on the market. 

He also talks about extrapolation and interchangeability as well as where some biosimilars stand in both ASCO and NCCN guidelines for patients who are going into supportive care. 

And Ilana Yurkiewicz, MD (https://stanford.io/2RXPixR), talks about what the word "cure" means to you compared to what it means to patients in a world with OS, PFS, DFS, CR, etc. (26:35). 

Subscribe here:

Apple Podcasts
Google Podcasts

Show Notes

By Hitomi Hosoya, MD, PhD

- Biosimilars are biologic products that are highly similar to the reference products with no clinically meaningful difference in terms of safety, efficacy, purity, and potency.

- Unlike “generic” products, biosimilars are produced in living systems, therefore they cannot be replicated identically. 

- The Food and Drug Administration encourages companies to produce biosimilars as a patent expires on the original product.

- For approval, the FDA requires largely preclinical data; amino acid sequence and molecular structures, pharmacodynamics and pharmacokinetic data in animal models and humans. Also, no greater immunogenicity should be demonstrated.

- Large randomized trials are not usually required for approval of biosimilars as there is already data on the original product. Post-marketing surveillance is important.

- 14 biosimilars have already been approved by the FDA.

- Interchangeable designation of biosimilars is yet to come.

- At this early stage of biosimilar marketing, we see a 10%-11% cost reduction. This is expected to increase as the market expands.

References:

 JAMA Oncol.2018 Feb 1;4(2):241-247

 JCSO 2018;16(6):e283-e289.

Contact us: [email protected]

MDedge Hematology/Oncology Twitter: @MDedgeHemOnc

Ilana Yurkiewicz Twitter: @ilanayurkiewicz

 

In this episode, Gary H. Lyman, MD (https://bitly.is/2UJzUly) joins David Henry, MD, (http://bit.ly/2MFDfzm) to talk about biosimilars. 

Dr. Lyman talks about the definition of biosimilars, how they are made, which are approved, and which ones are on the market. 

He also talks about extrapolation and interchangeability as well as where some biosimilars stand in both ASCO and NCCN guidelines for patients who are going into supportive care. 

And Ilana Yurkiewicz, MD (https://stanford.io/2RXPixR), talks about what the word "cure" means to you compared to what it means to patients in a world with OS, PFS, DFS, CR, etc. (26:35). 

Subscribe here:

Apple Podcasts
Google Podcasts

Show Notes

By Hitomi Hosoya, MD, PhD

- Biosimilars are biologic products that are highly similar to the reference products with no clinically meaningful difference in terms of safety, efficacy, purity, and potency.

- Unlike “generic” products, biosimilars are produced in living systems, therefore they cannot be replicated identically. 

- The Food and Drug Administration encourages companies to produce biosimilars as a patent expires on the original product.

- For approval, the FDA requires largely preclinical data; amino acid sequence and molecular structures, pharmacodynamics and pharmacokinetic data in animal models and humans. Also, no greater immunogenicity should be demonstrated.

- Large randomized trials are not usually required for approval of biosimilars as there is already data on the original product. Post-marketing surveillance is important.

- 14 biosimilars have already been approved by the FDA.

- Interchangeable designation of biosimilars is yet to come.

- At this early stage of biosimilar marketing, we see a 10%-11% cost reduction. This is expected to increase as the market expands.

References:

 JAMA Oncol.2018 Feb 1;4(2):241-247

 JCSO 2018;16(6):e283-e289.

Contact us: [email protected]

MDedge Hematology/Oncology Twitter: @MDedgeHemOnc

Ilana Yurkiewicz Twitter: @ilanayurkiewicz

 

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.

Rise in HCV linked to OxyContin reformulation

Article Type
Changed
Thu, 02/07/2019 - 09:06

 

HIV/AIDs, pediatric cancer research, abortion, prescription drug prices, and preexisting conditions were among the health care highlights in President Donald Trump’s second State of the Union Address. Also today, public health experts have attributed to the opioid epidemic the recent alarming rise in the rate of hepatitis C virus infection. medical advice prompts unneeded emergency visits by patients with atrial fibrillation, and legal marijuana may complicate substance use disorder treatment in adolescents.

Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Publications
Sections

 

HIV/AIDs, pediatric cancer research, abortion, prescription drug prices, and preexisting conditions were among the health care highlights in President Donald Trump’s second State of the Union Address. Also today, public health experts have attributed to the opioid epidemic the recent alarming rise in the rate of hepatitis C virus infection. medical advice prompts unneeded emergency visits by patients with atrial fibrillation, and legal marijuana may complicate substance use disorder treatment in adolescents.

Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

 

HIV/AIDs, pediatric cancer research, abortion, prescription drug prices, and preexisting conditions were among the health care highlights in President Donald Trump’s second State of the Union Address. Also today, public health experts have attributed to the opioid epidemic the recent alarming rise in the rate of hepatitis C virus infection. medical advice prompts unneeded emergency visits by patients with atrial fibrillation, and legal marijuana may complicate substance use disorder treatment in adolescents.

Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica